Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
3(38%)
Results Posted
133%(4 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_1
2
25%
Ph phase_2
5
63%
Ph phase_3
1
13%

Phase Distribution

2

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
5(62.5%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

3

trials recruiting

Total Trials

8

all time

Status Distribution
Active(3)
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated2
Active, not recruiting2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
3
Success Rate
60.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (25.0%)
Phase 25 (62.5%)
Phase 31 (12.5%)

Trials by Status

terminated225%
recruiting113%
active_not_recruiting225%
completed338%

Recent Activity

3 active trials
Showing 5 of 8
active_not_recruitingphase_2

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

NCT01424982
active_not_recruitingphase_3

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

NCT04530565
recruitingphase_2

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

NCT01746836
terminatedphase_1

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

NCT03576547
completedphase_2

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

NCT02272998
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT01424982Phase 2

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT04530565Phase 3

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Active Not Recruiting
NCT01746836Phase 2

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

Recruiting
NCT03576547Phase 1

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

Terminated
NCT02272998Phase 2

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

Completed
NCT01620216Phase 2

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Terminated
NCT02265341Phase 2

Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions

Completed
NCT02779283Phase 1

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8